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Many respiratory diseases, but this is also 
true for other diseases, including asthma 
and chronic obstructive pulmonary dis-
ease (COPD), should be more properly 
defined as syndromes as they are charac-
terized by a high degree of heterogeneity. 
This heterogeneity is largely responsible for 
the variability in drug response. A strik-
ing example is COPD where patients with 
chronic bronchitis or emphysema who are 
completely different are classified under 
the same nosographic entity, principally 
on the basis of functional characteristics. 
Pharmacological response in so different 
clinical and pathological phenotypes can 
be very variable even when the same drug, 
at the same dose, for the same duration of 
treatment is administered. This can make 
it difficult the interpretation of clinical tri-
als in patients with COPD. Identification 
of patients who are more likely to respond 
to pharmacological treatment can increase 
the risk/benefit ratio in the individual 
patients and reduce health care costs. 
A promising example is the association 
between leukotriene receptor antagonists 
(LTRA) response in patients with asthma 
and genetic polymorphisms of the leuko-
triene pathway and/or receptors. A priori 
identification of LTRA responders among 
patients with asthma, that is currently 
based on a therapeutic trial, would enable 
to exploit the therapeutic effects of this 
class of drugs in the responders, avoiding 
exposure of non-responders to unjustifi-
able side effects and costs. More generally, 
a personalized pharmacotherapy of respi-
ratory diseases would improve manage-
ment of the individual patients, in terms 
of greater efficacy and safety, and reduce 
the health care costs. Personalized pharma-
cotherapy requires the implementation of 
more sophisticated diagnostic tools that 
should be based on a better understanding 
of the pathophysiology of respiratory dis-
eases and the development of sensitive and 
validated non-invasive techniques. There is 
no doubt that chronic airway  inflammation 
has a pivotal pathophysiological role in 
asthma. The most convincing evidence 
for that is the fact that anti-inflammatory 
drugs such as inhaled glucocorticoids are 
the most effective long-term treatment for 
asthma control. COPD is also character-
ized by lung inflammation, but the effi-
cacy of glucocorticoids in this disease is 
much lesser than in asthma indicating a 
different type of inflammation, relatively 
resistant to these drugs. At present, assess-
ment of airway inflammation is mainly 
based on invasive techniques including 
bronchoscopy and bronchial biopsies that 
cannot be used routinely or conventional 
diagnostic procedures including clinical 
assessment, pulmonary function test-
ing, bronchial challenge tests, and patient 
reported outcomes that are indirect meas-
ures of inflammation and/or lack sensitiv-
ity. In patients with asthma, measurement 
of fractional exhaled nitric oxide (F
E
NO) is 
a standardized, validated and well-accepted 
non-invasive surrogate marker of airway 
inflammation. F
E
NO analyzers provide 
immediate results and are cleared by the US 
Food and Drugs Administration for assess-
ing airway inflammation and monitoring 
therapy in patients with asthma. Compared 
with asthma control based on conventional 
outcomes, asthma control based on F
E
NO 
measurement enables a reduction of daily 
doses of inhaled glucocorticoids of about 
40% with similar efficacy and reduced 
costs and, likely, side effects. Although 
the clinical utility of this technique is still 
debated, many clinical trials on antiasth-
matic pharmacological treatment include 
F
E
NO among the outcome measures due 
to the importance of assessing drug effects 
based on their mechanisms of action, e.g., 
the effects of anti-inflammatory drugs 
on surrogate markers of inflammation. 
Analysis of eosinophil counts in induced 
sputum is a direct measure of airway 
inflammation that can be used for identify-
ing phenotypes of patients with asthma and 
COPD and predicting response to inhaled 
 glucocorticoids. However, this technique is 
difficult to be used routinely as it is semi-
invasive, is not well-accepted to patients, 
requires specialized staff and facilities, and 
is unfeasible in children. Advances in our 
understanding of the clinical pharmacol-
ogy of drugs for respiratory diseases should 
be attainable using measurements of vali-
dated biomarkers. Measurement of F
E
NO 
was a major breakthrough in patients with 
asthma and a relevant example of a surro-
gate marker of airway inflammation that 
translated effectively from basic research, 
through validation and standardization of 
the technique, to clinical setting. However, 
F
E
NO is only one surrogate marker of air-
way inflammation, useful in patients with 
asthma, particularly those with airway eosi-
nophilia, but unlikely to reflect the whole 
complexity of the inflammatory process in 
respiratory diseases and its multiple expres-
sions within a given  disease/syndrome. To 
better understand the pathophysiology of 
respiratory diseases, and its phenotypes, 
a molecular approach to the individual 
patients based on omics technologies is 
being implemented. These technologies 
include genomics, transcriptomics, pro-
teomics, lipidomics, metabolomics, and 
brethomics, a new omics technology that 
aims at identifying and quantifying breath 
biomolecules by reference analytical tech-
niques and identifying selective profiles 
of breath volatile organic compounds by 
electronic nose, a chemical sensor array. 
Omics technologies, that require close 
interdisciplinary interactions (bioengi-
neering, biophysics, bioinformatics), could 
have important implications for the phar-
macological treatment of respiratory dis-
eases: (1) identification of subphenotypes 
of patients with respiratory diseases that 
would facilitate the implementation of a 
tailored, personalized, pharmacotherapy; 
(2) unraveling novel potential targets for 
pharmacological intervention and devel-
opment of new drugs; (3) a better under-
standing of the mechanism(s) of action of 
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and costs. This requires a focus on the indi-
vidual patient, interdisciplinary work, and 
good, independent, research.
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nue to a personalized  pharmacotherapy. This 
requires a “handprint” for each single patient 
that should be based on the combination of 
conventional and novel techniques for the 
diagnosis and monitoring of pharmacologi-
cal therapy and robust systems biology for 
data analysis. Systems biology is also required 
for an unbiased approach to discovery of new 
biomarkers and/or pharmacological targets, 
which in turn might improve characteriza-
tion of patients and their treatment.
One of the major challenges in respira-
tory medicine is the identification of a per-
sonalized, tailored, pharmacotherapy that 
would optimize efficacy, tolerability, safety, 
currently available drugs that would result 
in a more rational use of these drugs and 
could suggest new pharmacological strate-
gies; (4) the evidence of ongoing pulmo-
nary inflammation in patients with no 
symptoms and maintained lung function 
that might require starting pharmacologi-
cal therapy.
Randomized clinical trials are still the best 
tool for assessing the pharmacological pro-
files of existing and new drugs, but their con-
clusions apply to large patient populations. 
The evidence of a large variability in drug 
response raises the issue of the best treatment 
for the individual patient and paves the ave-
